secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2026-08-10T20:03:45+00:00
Accession:  0001743881-26-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q2 revenue $243.7M, Attruby $222.4M; net loss $152.2M
---------------------------------------------------------------

- Q2 total revenue $243.7M vs $110.6M YoY; US Attruby net product revenue $222.4M.
- Net loss attributable to common stockholders $152.2M ($0.78/share) vs $181.9M ($0.95) year-ago.
- Cash and marketable securities $720.2M at Jun 30; $1B preferred equity closed Jul 1 led by Sixth Street.
- NDAs: BBP-418 PDUFA Nov 27 2026 (Priority Review), encaleret May 8 2027, infigratinib submitted.
- Real-world data: acoramidis 37% reduction in composite CV events vs tafamidis (TriNetX, p=0.002).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/0001743881-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000174388126000026/bbio-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001743881-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer